Jan Pyman

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 599 citations · Full text

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 432 citations · Full text

Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors

Ardian Latifi, Rodney B. Luwor, Maree Bilandzic et al. · PLoS ONE · 2012 · 234 citations · Full text

The molecular origin and taxonomy of mucinous ovarian carcinoma

Dane Cheasley, Matthew J. Wakefield, Georgina L. Ryland et al. · Nature Communications · 2019 · 180 citations · Full text

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

Lisa Vermij, Alicia León‐Castillo, Naveena Singh et al. · Modern Pathology · 2022 · 140 citations · Full text